Drugs / PEG-Asc
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable2 trials | ||||||
| — | NCT06916689 | Mar 2023 → Oct 2024 | polyp of colon | ASST Rhodense | Completed | No outcome recorded |
| — | NCT03849196 | Jul 2017 → Jan 2018 | — | Samsung Medical Center | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 3 | NCT07465705 Comparator | Sep 2025 → Mar 2026 overdue | — | NTC srl | Recruiting | No outcome recorded |
| Phase 3 | NCT02548403 Comparator | Jul → Sep 2014 | colorectal cancer | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02250196 Comparator | Mar → Sep 2013 | colon adenoma, colorectal cancer | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01509131 Comparator | Mar → Dec 2010 | — | Promefarm S.r.l. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-Asc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02548403 ↗ |
| Known as | PLENVU | “The bowel preparation product used consists of a very low-volume solution of Macrogol (3350) + Ascorbic Acid (1 liter) (PLENVU®, Norgine).” NCT06916689 ↗ |